Ware Olivia C 4

4 · Contineum Therapeutics, Inc. · Filed Jun 26, 2026

AI-generated summary of this filing

Updated Jun 26, 2026

Contineum (CTNM) Director Olivia Ware Receives 19,000-Share Option

What Happened

Olivia C. Ware, a director of Contineum Therapeutics, was granted a derivative award (stock option) for 19,000 shares on 2026-06-26. The Form 4 reports an acquisition (code A) at $0.00 per share (no cash paid at grant). This is a compensation grant, not an open-market purchase or sale.

Key Details

Transaction date: 2026-06-26; transaction type: Award/Grant (derivative) for 19,000 shares; reported price: $0.00.
Vesting: Option vests in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting, subject to continued service (per footnote referencing the 2024 Equity Incentive Plan and the Non‑Employee Director Compensation Program).
Shares owned after transaction: not specified in the provided filing excerpt.
Filing timeliness: Reported on 2026-06-26 for a transaction on the same date (appears timely).
Transaction code: A (award/grant); reported as a derivative transaction.

Context

This is a routine director compensation grant under the company’s equity plan, intended to compensate non-employee board members. It does not represent an immediate purchase of shares and may not indicate the director’s view on the company’s near-term stock performance.

Form 4

Period: 2026-06-26

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-06-26+19,000→ 19,000 total
Exercise: $14.19Exp: 2036-06-25→ Class A Common Stock (19,000 underlying)

Footnotes (1)

[F1]Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-06-26

1 file